Manatt Health Senior Advisor Ian Spatz was quoted in MedPage Today on President Biden’s executive order aimed at improving competition in the prescription drug space. The publication reported that Biden highlighted that “it is also the policy of my administration to support aggressive legislative reforms that would lower prescription drug prices, including by allowing Medicare to negotiate drug prices.” However, Spatz warned to be cautious about the order’s effects. “Like any executive order, this is more about signaling priorities than about legally binding changes,” Spatz explained. “For prescription drugs, the executive order lists many items that are already in the works. Most impactful may be its call for creating standardized health plans in the ACA [Affordable Care Act] exchanges.” He added that how those plans treat prescription drug coverage could be impactful.
Read the full article here.